Charles Craig

1.4k total citations
38 papers, 1.1k citations indexed

About

Charles Craig is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Charles Craig has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 33 papers in Virology and 11 papers in Epidemiology. Recurrent topics in Charles Craig's work include HIV Research and Treatment (33 papers), HIV/AIDS drug development and treatment (32 papers) and HIV/AIDS Research and Interventions (20 papers). Charles Craig is often cited by papers focused on HIV Research and Treatment (33 papers), HIV/AIDS drug development and treatment (32 papers) and HIV/AIDS Research and Interventions (20 papers). Charles Craig collaborates with scholars based in United States, United Kingdom and South Africa. Charles Craig's co-authors include Michael Monsour, Xierong Wei, LI Jin-fen, David M. Irlbeck, Jeffrey A. Johnson, Walid Heneine, Paul Sandstrom, Amanda Smith, Jonathan Lipscomb and E. Randall Lanier and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Virology.

In The Last Decade

Charles Craig

38 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Craig United States	17	851	747	240	128	91	38	1.1k
Jean‐Claude Schmit Luxembourg	23	1.0k 1.2×	1.0k 1.4×	250 1.0×	141 1.1×	160 1.8×	51	1.4k
Maria Cecília Araripe Sucupira Brazil	18	654 0.8×	646 0.9×	252 1.1×	118 0.9×	79 0.9×	59	966
Joseph Quinn United States	11	1.3k 1.5×	1.0k 1.4×	351 1.5×	96 0.8×	135 1.5×	14	1.6k
Annemarie M. J. Wensing Netherlands	13	1.6k 1.8×	1.4k 1.9×	333 1.4×	214 1.7×	127 1.4×	23	1.8k
Alex R. Rinehart United States	17	837 1.0×	606 0.8×	230 1.0×	106 0.8×	41 0.5×	43	1.1k
Winai Ratanasuwan Thailand	16	808 0.9×	594 0.8×	257 1.1×	120 0.9×	73 0.8×	38	957
Esther Race France	15	957 1.1×	915 1.2×	117 0.5×	81 0.6×	79 0.9×	19	1.1k
Sharon L. Benoit United States	5	1.0k 1.2×	973 1.3×	232 1.0×	59 0.5×	76 0.8×	8	1.2k
Joakim Esbjörnsson Sweden	15	629 0.7×	750 1.0×	256 1.1×	93 0.7×	49 0.5×	51	902
Michael Wohlfeiler United States	14	758 0.9×	637 0.9×	280 1.2×	82 0.6×	81 0.9×	31	1.1k

Countries citing papers authored by Charles Craig

Since Specialization

Citations

This map shows the geographic impact of Charles Craig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Craig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Craig more than expected).

Fields of papers citing papers by Charles Craig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Craig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Craig. The network helps show where Charles Craig may publish in the future.

Co-authorship network of co-authors of Charles Craig

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Craig. A scholar is included among the top collaborators of Charles Craig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Craig. Charles Craig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nel, Annaléne, Neliëtte van Niekerk, Ben Van Baelen, et al.. (2021). Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. The Lancet HIV. 8(2). e77–e86. 71 indexed citations

Heera, Jayvant, Srinivas Rao Valluri, Charles Craig, et al.. (2019). First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.. PubMed. 42(2). 101–107. 1 indexed citations

Lewis, Marilyn, Julie Mori, Jonathan Toma, et al.. (2018). Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials. PLoS ONE. 13(12). e0204099–e0204099. 10 indexed citations

Stellbrink, Hans-Jürgen, Andrew Carr, Michael S. Saag, et al.. (2016). Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. AIDS. 30(8). 1229–1238. 31 indexed citations

Snedecor, Sonya J., Lavanya Sudharshan, Kit N. Simpson, et al.. (2014). Burden of Nonnucleoside Reverse Transcriptase Inhibitor Resistance in HIV-1-Infected Patients: A Systematic Review and Meta-Analysis. AIDS Research and Human Retroviruses. 30(8). 753–768. 12 indexed citations

Heera, Jayvant, Srinivas Rao Valluri, Charles Craig, et al.. (2014). First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN. Journal of the International AIDS Society. 17(4S3). 19519–19519. 5 indexed citations

DeJesus, Edwin, Gerd Fätkenheuer, Catherine Orrell, et al.. (2014). Efficacy and Safety of Lersivirine Versus Etravirine for the Treatment of HIV-1 Infection in Patients with Prior Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and Evidence of NNRTI Resistance: A Randomized Phase 2B Trial. HIV Clinical Trials. 15(5). 209–217. 1 indexed citations

Vernazza, Pietro, Cunshan Wang, Anton Pozniak, et al.. (2013). Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2). 171–179. 16 indexed citations

Portsmouth, Simon, Srinivas Rao Valluri, Martin Däumer, et al.. (2012). Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078. Antiviral Research. 97(1). 60–65. 7 indexed citations

10.

Mills, Anthony, Donna Mildvan, Daniel Podzamczer, et al.. (2012). Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2). 164–170. 30 indexed citations

11.

Fidock, Mark, Carl Laxton, Peter Colman, et al.. (2011). The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691). Clinical Pharmacology & Therapeutics. 89(6). 821–829. 64 indexed citations

12.

Sierra‐Madero, Juan, Giovanni Di Perri, Robin Wood, et al.. (2010). Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study. HIV Clinical Trials. 11(3). 125–132. 49 indexed citations

13.

Portsmouth, Simon, Srinivas Rao Valluri, Bernhard Thiele, et al.. (2010). Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study. Journal of the International AIDS Society. 13. P128–P128. 1 indexed citations

14.

Molina, Jean‐Michel, Mounir Ait‐Khaled, Rita Rinaldi, et al.. (2009). Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. Journal of Antimicrobial Chemotherapy. 64(2). 398–410. 8 indexed citations

15.

Johnson, Jeffrey A., LI Jin-fen, Xierong Wei, et al.. (2008). Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy. PLoS Medicine. 5(7). e158–e158. 291 indexed citations

16.

Hazen, Richard, Victoria L. Harvey, Robert G. Ferris, et al.. (2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrobial Agents and Chemotherapy. 51(9). 3147–3154. 26 indexed citations

17.

Kline, Mark W., Richard C. Brundage, Courtney V. Fletcher, et al.. (2001). Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. The Pediatric Infectious Disease Journal. 20(7). 666–671. 12 indexed citations

18.

Para, Michael F., David V. Glidden, Robert W. Coombs, et al.. (2000). Baseline Human Immunodeficiency Virus Type 1 Phenotype, Genotype, and RNA Response after Switching from Long‐Term Hard‐Capsule Saquinavir to Indinavir or Soft‐Gel–Capsule Saquinavir in AIDS Clinical Trials Group Protocol 333. The Journal of Infectious Diseases. 182(3). 733–743. 30 indexed citations

19.

Craig, Charles, Esther Race, Lynne Whittaker, et al.. (1998). HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS. 12(13). 1611–1618. 52 indexed citations

20.

Streith, Jacques, Charles Craig, Marc Müller, & Théophile Tschamber. (1993). β-lactam derivatives from 1-H-1,2-diazepines. Bioorganic & Medicinal Chemistry Letters. 3(11). 2375–2378. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact